Study details
Enrolling now
A Study to Determine the Preferred Dose of Lisinopril for Preventing Urinary Toxicity Following Radiotherapy for Prostate Cancer
University of Rochester
NCT IDNCT05530655ClinicalTrials.gov data as of Apr 2026
Phase
EARLY_PHASE1
Target enrollment
30
Study length
about 3.9 years
Ages
18–70
Sex
Male only
Locations
1 site in NY
About this study
This trial is testing a treatment called lisinopril to see if it can prevent urinary problems in men with prostate cancer who are receiving radiation therapy. The goal is to find the best dose of lisinopril and understand how it affects urine symptoms, biomarkers, and their connection to those symptoms.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Lisinopril Tablets
PhaseEARLY_Phase 1
DrugLisinopril Tablets
Routeoral
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low8%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug classes
lisinopril (ACE inhibitor; blocks angiotensin-converting enzyme to lower blood pressure)
Drug routes
oral (Oral Tablet)
Body systems
Oncology